Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

A Phase 1 Study of Azacitidine in Combination with Evorpacept for Higher-Risk Myelodysplastic Syndrome (MDS); ASPEN-02

Post navigation

Previous: Evorpacept, a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Next: A Phase 1 Investigator-Initiated Trial of Evorpacept (ALX148), Lenalidomide and Rituximab for Patients with Relapsed or Refractory B-Cell non-Hodgkin lymphoma

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn Level Access